RESUMO
OBJECTIVES: To evaluate and describe brainstem auditory-evoked response measurements in healthy African pygmy hedgehogs (Atelerix albiventris). MATERIALS AND METHODS: Brainstem auditory-evoked response measurements were performed in 12 adult African pygmy hedgehogs (seven males, five females) under general anaesthesia. Waveform morphology was assessed and wave latencies, amplitudes and interpeak latencies calculated. RESULTS: Brainstem auditory-evoked response measurements were successfully performed in both ears from all hedgehogs. Three distinct waves were reproducible in all patients in both ears using a stimulus with an intensity of 90 dB nHL (decibel above normal hearing level). Amplitudes of waves I and V, latencies of waves I, II-III and V and interpeak latencies of waves I-V were calculated at 90 dB for both ears of each animal. CLINICAL SIGNIFICANCE: This study describes normal brainstem auditory-evoked response morphology and latencies for African pygmy hedgehogs. General anaesthesia is required to perform this neurodiagnostic, given the unique behaviour and anatomy of hedgehogs. This baseline data may be useful for investigating hearing abnormalities and central nervous system disorders in hedgehogs.
Assuntos
Potenciais Evocados Auditivos do Tronco Encefálico , Ouriços , Animais , Tronco Encefálico , Feminino , MasculinoRESUMO
OBJECTIVES: To evaluate the sedative and cardiorespiratory effects of alfaxalone in ball pythons following subcutaneous administration in the cranial versus caudal third of the body. MATERIALS AND METHODS: In a prospective, randomised, blinded, complete crossover study, eight ball pythons ( Python regius ) received alfaxalone in the cranial or caudal third of the body. Sedative and cardiorespiratory parameters were recorded. RESULTS: Administration of alfaxalone in the cranial third of the body resulted in significantly deeper and longer sedation compared with administration in the caudal third of the body. Righting reflex was lost in five of eight snakes following cranial injection compared with one of eight snakes after caudal injection. Jaw tone was lost in all snakes following cranial injection and intubation was successfully performed in seven. In contrast, snakes did not lose jaw tone and intubation was not possible following caudal injection. Heart rate and respiratory rate were significantly decreased following administration of alfaxalone in the cranial third of the body. CLINICAL SIGNIFICANCE: Administration of drugs that undergo hepatic metabolism or excretion should not be performed in the caudal third of the body in snakes, because it can result in significantly reduced drug efficacy. A hepatic first-pass effect is assumed to be the most likely underlying cause for the observed effect because part of the venous return from the caudal body flows directly to the liver.
Assuntos
Anestesia/veterinária , Anestésicos/administração & dosagem , Boidae/fisiologia , Pregnanodionas/administração & dosagem , Anestesia/métodos , Anestésicos/farmacologia , Animais , Estudos Cross-Over , Feminino , Injeções Subcutâneas/métodos , Injeções Subcutâneas/veterinária , Masculino , Pregnanodionas/farmacologia , Estudos Prospectivos , Distribuição AleatóriaRESUMO
OBJECTIVE: To determine the vertebral heart size in chinchillas using right and left lateral radiographic views and CT images. To evaluate the agreement between radiographic and CT modalities. METHODS: Twenty-one clinically healthy chinchillas and seven chinchillas with cardiovascular abnormalities underwent cardiovascular examination before thoracic radiographs and thoracic CT obtained under dexmedetomidine-ketamine anaesthesia. Two observers calculated vertebral heart size for radiographic and CT studies. Reference intervals were calculated with the robust method. Agreement between radiographic and CT-derived vertebral heart size was evaluated with Bland-Altman plots and Deming regression. RESULTS: Mean ±sd vertebral heart size for lateral radiographs was 8·9 ±0·62 (reference interval: 7·5 to 10·2) and for CT-derived vertebral heart size was 8·2 ±0·55 (reference interval: 7·1 to 9·4). CT significantly underestimated the radiographic vertebral heart size by 0·66 vertebrae. There was no significant difference between vertebral heart size for right and left lateral radiographic views, or between female and male chinchillas. CLINICAL SIGNIFICANCE: Radiographic vertebral heart size for chinchillas is larger than that reported for similar rodents. Vertebral heart size can be calculated using radiography or CT in chinchillas, but these techniques are not interchangeable.
Assuntos
Chinchila/anatomia & histologia , Coração/anatomia & histologia , Coração/diagnóstico por imagem , Radiografia Torácica/veterinária , Tomografia Computadorizada por Raios X/veterinária , Animais , Doenças Cardiovasculares/veterinária , Feminino , Masculino , Tamanho do Órgão , Vértebras Torácicas/anatomia & histologia , Vértebras Torácicas/diagnóstico por imagemRESUMO
Human angiofibromas are rare and arise typically in the nasopharynx. In veterinary medicine they have only been described in the dog. Microscopically, angiofibromas consist of irregular groups of blood vessels within a stroma of connective tissue, with oedema and secondary inflammation often present. A cockatiel (Nymphicus hollandicus) was presented with an oral mass that consisted of aggregates of blood vessels surrounded by a connective tissue stroma, with the presence of oedema and secondary inflammation. Tumours of the oral cavity are uncommon in birds and to the authors' knowledge this is the first case of avian angiofibroma.
Assuntos
Angiofibroma/veterinária , Doenças das Aves/patologia , Cacatuas , Neoplasias Bucais/veterinária , Angiofibroma/patologia , Animais , Feminino , Neoplasias Bucais/patologiaRESUMO
The metabolism and excretion of taranabant (MK-0364, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2{[5-(trifluoromethyl)pyridine-2-yl]oxy}propanamide), a potent cannabinoid-1 receptor inverse agonist, were evaluated in rats and rhesus monkeys. Following administration of [¹4C]taranabant, the majority of the radioactivity was excreted within 72 h. In both rats and rhesus monkeys, taranabant was eliminated primarily via oxidative metabolism, followed by excretion of metabolites into bile. Major pathways of metabolism that were common to rats and rhesus monkeys included hydroxylation at the benzylic carbon adjacent to the cyanophenyl ring to form a biologically active circulating metabolite M1, and oxidation of one of the two geminal methyl groups of taranabant or M1 to the corresponding diastereomeric carboxylic acids. Oxidation of the cyanophenyl ring, followed by conjugation with glutathione or glucuronic acid, was a major pathway of metabolism only in the rat and was not detected in the rhesus monkey. Metabolism profiles of taranabant in liver microsomes in vitro were qualitatively similar in rats, rhesus monkeys and humans and included formation of M1 and oxidation of taranabant or M1 to the corresponding carboxylic acids via oxidation of a geminal methyl group. In human liver microsomes, metabolism of taranabant was mediated primarily by CYP3A4.
Assuntos
Amidas/metabolismo , Agonismo Inverso de Drogas , Piridinas/metabolismo , Receptor CB1 de Canabinoide/agonistas , Receptor CB1 de Canabinoide/antagonistas & inibidores , Amidas/sangue , Amidas/química , Amidas/farmacocinética , Animais , Anticorpos Monoclonais/farmacologia , Líquidos Corporais/metabolismo , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Feminino , Haplorrinos , Humanos , Cetoconazol/farmacologia , Espectroscopia de Ressonância Magnética , Masculino , Espectrometria de Massas , Microssomos Hepáticos/efeitos dos fármacos , Microssomos Hepáticos/metabolismo , Piridinas/sangue , Piridinas/química , Piridinas/farmacocinética , Radioatividade , RatosRESUMO
The aim was to investigate the metabolic activation potential of a pentafluorophenylethylamine derivative (compound I) in vitro in the rat and to identify the cytochrome P450 (CYP) enzymes that catalyse these metabolic activation processes. Reduced glutathione (GSH) was fortified in rat hepatocytes and liver microsomes to trap possible reactive intermediates. Four glutathione conjugates (M1-4) were identified by LC-MS(n) following incubation of compound I in GSH-enriched rat hepatocytes and liver microsomes. Three of these conjugates (M2-4) have not been reported previously for pentafluorophenyl derivatives. Elemental composition analysis of these conjugates was obtained using high-resolution quadrupole time-of-flight mass spectrometry. The formation of GSH conjugate M1 was rationalized as a direct nucleophilic replacement of fluoride by glutathione, whereas the formation of the GSH conjugates M2-4 was proposed to occur by NADPH-dependent metabolic activation of the pentafluorophenyl ring via arene oxide, quinone and/or quinoneimine reactive intermediates. Formation of these conjugates was enhanced three- to five-fold in liver microsomes obtained from phenobarbital- and dexamethasone-treated rats. In incubations with pooled rat liver microsomes and recombinant rat CYP3A1 and CYP3A2, troleandomycin (TAO) reduced the formation of GSH conjugates M2-4 by 80-90%, but it had no effect on the formation of M1. Incubation of compound I with rat supersomes indicated that only CYP3A1 and CYP3A2 were capable of mediating these metabolic activation processes.
Assuntos
Sistema Enzimático do Citocromo P-450/metabolismo , Glutationa/metabolismo , Hepatócitos/enzimologia , Microssomos Hepáticos/enzimologia , Fenetilaminas/farmacocinética , Animais , Antibacterianos/metabolismo , Antibacterianos/farmacologia , Biotransformação , Técnicas In Vitro , Masculino , Fenetilaminas/administração & dosagem , Fenetilaminas/metabolismo , Ratos , Ratos Sprague-Dawley , Troleandomicina/metabolismo , Troleandomicina/farmacologiaRESUMO
Methods for the quantitative determination of efavirenz in human plasma and the qualitative assessment of the stereochemical integrity of efavirenz in post-dose human plasma samples are described. After the addition of an internal standard, plasma samples were extracted with hexane-methylene chloride (65/35, v/v%). The extracts were evaporated to dryness and reconstituted in mobile phase. Upon exposure to UV light, the analyte was found to form fluorescent products; the major fluorescent product was isolated and identified as a substituted quinoline. Thus, the plasma extracts were analyzed via HPLC with post-column photochemical derivatization and fluorescence detection. Reverse phase chromatography was used for the quantitative assay, whereas chromatography with a column containing a chiral stationary phase (dinitrobenzoyl leucine) was used for the stereochemical assessment. The quantitative assay has been validated in the concentration range of 50-1000 ng/ml using 0.5 ml samples. Analyte recovery was better than 89% at all points on the standard curve. Intra-day precision was better than 5% C.V., while accuracy was between 95 and 104% of nominal over the range of the assay. The selective detection method reduces the likelihood of interference by co-administered medications or endogenous species. The stereochemical configuration of efavirenz was confirmed to remain intact in post-dose human plasma samples. The quantitative method has been successfully utilized to support a study in which a possible drug interaction between co-administered HIV protease inhibitors and efavirenz was evaluated.
Assuntos
Oxazinas/sangue , Inibidores da Transcriptase Reversa/sangue , Alcinos , Benzoxazinas , Cromatografia Líquida de Alta Pressão , Ciclopropanos , Humanos , Indicadores e Reagentes , Espectroscopia de Ressonância Magnética , Oxazinas/farmacocinética , Fotoquímica , Fotólise , Controle de Qualidade , Inibidores da Transcriptase Reversa/farmacocinética , Espectrometria de Fluorescência , Espectrofotometria Ultravioleta , EstereoisomerismoRESUMO
The metabolism of diclofenac has been reported to produce reactive benzoquinone imine intermediates. We describe the identification of mercapturic acid derivatives of diclofenac in rats and humans. Three male Sprague-Dawley rats were administered diclofenac in aqueous solution (pH 7) at 50 mg/kg by intraperitoneal injection, and urine was collected for 24 h. Human urine specimens were obtained, and samples were pooled from 50 individuals. Urine samples were analyzed by liquid chromatography-tandem mass spectrometry (LC/MS/MS). Two metabolites with MH(+) ions at m/z 473 were detected in rat urine and identified tentatively as N-acetylcysteine conjugates of monohydroxydiclofenac. Based upon collision-induced fragmentation of the MH(+) ions, accurate mass measurements of product ions, and comparison of LC/MS/MS properties of the metabolites with those of synthetic reference compounds, one metabolite was assigned as 5-hydroxy-4-(N-acetylcystein-S-yl)diclofenac and the other as 4'-hydroxy-3'-(N-acetylcystein-S-yl)diclofenac. The former conjugate also was detected in the pooled human urine sample by multiple reaction-monitoring LC/MS/MS analysis. It is likely that these mercapturic acid derivatives represent degradation products of the corresponding glutathione adducts derived from diclofenac-2,5-quinone imine and 1',4'-quinone imine, respectively. Our data are consistent with previous findings, which suggest that oxidative bioactivation of diclofenac in humans proceeds via benzoquinone imine intermediates.
Assuntos
Acetilcisteína/urina , Benzoquinonas/metabolismo , Diclofenaco/farmacocinética , Animais , Biotransformação , Cromatografia Líquida de Alta Pressão , Humanos , Iminas/metabolismo , Masculino , Espectrometria de Massas , Ratos , Ratos Sprague-DawleyRESUMO
[reaction: see text]. Radical cyclization of 6 affords the bicyclic vinyl ether 9 with the appropriate stereochemistry for elaboration (seven steps) to griseolic acid B (1).
Assuntos
Adenosina/análogos & derivados , Adenosina/síntese química , Inibidores de Fosfodiesterase/síntese química , 3',5'-AMP Cíclico Fosfodiesterases/antagonistas & inibidores , Ciclização , Indicadores e Reagentes , Espectroscopia de Ressonância Magnética , Oxirredução , Estereoisomerismo , Streptomyces/químicaRESUMO
The liposidomycins comprise a family of complex nucleoside antibiotics that inhibit bacterial peptidoglycan synthesis. Their structures (1, 2) feature nucleoside, ribofuranoside, diazepanone, and lipid regions. Several stereogenic centers remain unassigned, including three within the diazepanone region: C-6', C-2'", and C-3'". An intramolecular reductive amination reaction has been used to prepare model diazepanones. Analysis of 40 and two of its diastereomers by NMR spectroscopy, X-ray crystallography, and molecular modeling indicates a close relative configurational and conformational match between 40 and the liposidomycin diazepanone degradation product 43 and allows the assignment of stereochemistry of the natural products as either [C-6'(R), C-2'"(R), C-3'"(R)] or [C-6'(S), C-2'"(S), C-3'"(S)].
Assuntos
Aminoglicosídeos , Antibacterianos/síntese química , Aminação , Antibacterianos/química , Modelos Moleculares , Conformação Molecular , Oxirredução , Estereoisomerismo , Valina/análogos & derivados , Valina/químicaRESUMO
The nonsteroidal anti-inflammatory drug diclofenac causes a rare but potentially fatal hepatotoxicity that may be associated with the formation of reactive metabolites. In this study, three glutathione (GSH) adducts, namely 5-hydroxy-4-(glutathion-S-yl)diclofenac (M1), 4'-hydroxy-3'-(glutathion-S-yl)diclofenac (M2), and 5-hydroxy-6-(glutathion-S-yl)diclofenac (M3), were identified by liquid chromatography-tandem mass spectrometry analysis of bile from Sprague-Dawley rats injected i.p. with a single dose of diclofenac (200 mg/kg). These adducts presumably were formed via hepatic cytochrome P-450 (CYP)-catalyzed oxidation of diclofenac to reactive benzoquinone imines that were trapped by GSH conjugation. In support of this hypothesis, M1, M2, and M3 were generated from diclofenac in incubations with rat liver microsomes in the presence of NADPH and GSH. Increases in adduct formation were observed when incubations were performed with liver microsomes from phenobarbital- or dexamethasone-treated rats. Adduct formation was inhibited by polyclonal antibodies against CYP2B, CYP2C, and CYP3A (40-50% inhibition at 5 mg of IgG/nmol of CYP) but not by an antibody against CYP1A. Maximal inhibition was obtained when the three inhibitory antibodies were used in a cocktail fashion (70-80% inhibition at 2.5 mg of each IgG/nmol of CYP). These data suggest that diclofenac undergoes biotransformation to reactive metabolites in rats and that CYP isoforms of the 2B, 2C, and 3A subfamilies are involved in this bioactivation process. With respect to CYP2C isoforms, rat hepatic CYP2C7 and CYP2C11 were implicated as mediators of the bioactivation based on immunoinhibition studies using antibodies specific to CYP2C7 and CYP2C11. Screening for GSH adducts also was carried out in human hepatocyte cultures containing diclofenac, and M1, M2, and M3 again were detected. It is possible, therefore, that reactive benzoquinone imines may be formed in vivo in humans and contribute to diclofenac-mediated hepatic injury.
Assuntos
Anti-Inflamatórios não Esteroides/farmacocinética , Sistema Enzimático do Citocromo P-450/metabolismo , Diclofenaco/farmacocinética , Glutationa/metabolismo , Microssomos Hepáticos/metabolismo , Animais , Bile/metabolismo , Biotransformação , Células Cultivadas , Cromatografia Líquida , Feminino , Humanos , Masculino , Espectrometria de Massas , Microssomos Hepáticos/enzimologia , Ratos , Ratos Sprague-DawleyRESUMO
Cytochrome P450 2C11 in rats was recently found to metabolize diclofenac into a highly reactive product that covalently bound to this enzyme before it could diffuse away and react with other proteins. To determine whether cytochromes P450 in human liver could catalyze a similar reaction, we have studied the covalent binding of diclofenac in vitro to liver microsomes of 16 individuals. Only three of 16 samples were found by immunoblot analysis to activate diclofenac appreciably to form protein adducts in a NADPH-dependent pathway. Cytochrome P450 2C9, which catalyzes the major route of oxidative metabolism of diclofenac to produce 4'-hydroxydiclofenac, did not appear to be responsible for the formation of the protein adducts, because sulfaphenazole, an inhibitor of this enzyme, did not affect protein adduct formation. In contrast, troleandomycin, an inhibitor of P450 3A4, inhibited both protein adduct formation and 5-hydroxylation of diclofenac. These findings were confirmed with the use of baculovirus-expressed human P450 2C9 and P450 3A4. One possible reactive intermediate that would be expected to bind covalently to liver proteins was the p-benzoquinone imine derivative of 5-hydroxydiclofenac. This product was formed by an apparent metal-catalyzed oxidation of 5-hydroxydiclofenac that was inhibited by EDTA, glutathione, and NADPH. The p-benzoquinone imine decomposition product bound covalently to human liver microsomes in vitro in a reaction that was inhibited by GSH. In contrast, GSH did not prevent the covalent binding of diclofenac to human liver microsomes. These results suggest that for appreciable P450-mediated bioactivation of diclofenac to occur in vivo, an individual may have to have both high activities of P450 3A4 and perhaps low activities of other enzymes that catalyze competing pathways of metabolism of diclofenac. Moreover, the p-benzoquinone imine derivative of 5-hydroxydiclofenac probably has a role in covalent binding in the liver only under the conditions where levels of NADPH, GSH, and other reducing agents would be expected to be low.
Assuntos
Anti-Inflamatórios não Esteroides/metabolismo , Hidrocarboneto de Aril Hidroxilases , Sistema Enzimático do Citocromo P-450/metabolismo , Diclofenaco/análogos & derivados , Diclofenaco/metabolismo , Microssomos Hepáticos/enzimologia , Oxigenases de Função Mista/metabolismo , Esteroide 16-alfa-Hidroxilase , Animais , Anti-Inflamatórios não Esteroides/química , Citocromo P-450 CYP3A , Cromatografia Gasosa-Espectrometria de Massas , Humanos , Masculino , Ratos , Ratos Sprague-Dawley , Esteroide Hidroxilases/metabolismoRESUMO
Montelukast sodium [1-([(1(R)-(3-(2-(7-chloro-2-quinolinyl)-(E)- ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio]methyl)cyclopropylacetic acid sodium salt] (MK-476, Singulair) is a potent and selective antagonist of the cysteinyl leukotriene (Cys-LT1) receptor and is under investigation for the treatment of bronchial asthma. To assess the metabolism and excretion of montelukast, six healthy subjects received single oral doses of 102 mg of [14C]montelukast, and the urine and feces were collected. Most of the radioactivity was recovered in feces, with =0.2% appearing in urine. Based on these results and the reported modestly high oral bioavailability of montelukast, it could be concluded that a major part of the radioactivity was excreted via bile. A second clinical study was conducted to identify biliary metabolites of montelukast. The bile was aspirated using a modified procedure involving a nasogastric tube placed fluoroscopically near the ampulla of Vater, after an oral dose of 54.8 mg of [14C]montelukast. This technique appears to be a new application for drug metabolism studies. The study was conducted with fasted and nonfasted subjects, with the bile being aspirated continuously under suction over periods of 2-8 hr and 8-12 hr after the dose, respectively. Two hours before the end of the collection procedure, cholecystokinin carboxyl-terminal octapeptide was administered iv to stimulate gallbladder contraction. Plasma samples also were collected periodically over 10 hr. Due to the nature of the collection procedure and the limited sampling time, recovery of radioactivity in bile was incomplete and varied from 3 to 20% of the dose. Radiochromatographic and LC-MS/MS analyses of bile showed the presence of one major and several minor metabolites, along with small amounts of unchanged parent drug. The minor metabolites were identified, by LC-MS/MS comparison with synthetic standards or by NMR, as acyl glucuronide (M1), sulfoxide (M2), 25-hydroxy (a phenol, M3), 21-hydroxy (diastereomers of a benzylic alcohol, M5a and M5b), and 36-hydroxy (diastereomers of a methyl alcohol, M6a and M6b) analogs of montelukast. The major metabolite was characterized as a dicarboxylic acid (M4), a product of further oxidation of the hydroxymethyl metabolite M6. Chiral LC-MS/MS analyses of M4 revealed that this diacid, like M5 and M6, was formed in both diastereomeric forms. The levels of metabolites in the systemic circulation were low in the fed as well as fasted subjects, with <2% of the circulating radioactivity being due to metabolites M5a, M5b, M6a, and M6b. Overall, this bile aspiration technique, which is less invasive than either T-tube drainage or fine-needle percutaneous puncture, provided a convenient and expedient means of identifying the biliary metabolites of montelukast, relatively free of contributions from colonic microflora.
Assuntos
Acetatos/farmacocinética , Bile/metabolismo , Interleucina-1/metabolismo , Antagonistas de Leucotrienos , Quinolinas/farmacocinética , Acetatos/sangue , Adulto , Biotransformação , Cromatografia Líquida de Alta Pressão , Ciclopropanos , Feminino , Humanos , Masculino , Espectrometria de Massas , Pessoa de Meia-Idade , Quinolinas/sangue , SulfetosRESUMO
L-692,429 is a novel nonpeptidyl growth hormone secretagogue that has been demonstrated to stimulate growth hormone secretion in rats, dogs, and humans after intravenous administration. We have examined the pharmacokinetics and disposition of L-692,429 in male Sprague-Dawley rats, beagle dogs, and chimpanzees. Plasma clearance (CLp) of L-692,429 in dogs after intravenous dosing was approximately 18 ml/min/kg and was constant between the doses of 0.1 and 0.9 mg/kg. In rats, CLp after intravenous dosing increased from 3 to 12 ml/min/kg in a dose-dependent manner between 0.1 and 5 mg/kg. In chimpanzees, CLp after an intravenous dose of L-692,429 at 0.5 mg/kg was 5.7 ml/min/kg. In vitro binding of L-692,429 to plasma proteins of dogs, chimpanzees, and humans was approximately 87%, 94%, and 93.5%, respectively, and was independent of concentration. In contrast, plasma binding of L-692,429 was concentration-dependent in rats and decreased from 98.5% to 90.6% between 0.01 and 10 micrograms/ml. Metabolism of L-692,429 was minimal in rats, but moderate in dogs, with the major metabolite being a derivative monohydroxylated at the benzolactam moiety. Thus, the faster clearance of L-692,429 in dogs likely is caused by less extensive plasma protein binding and higher metabolic clearance. The nonlinear pharmacokinetics in rats probably is the result of concentration-dependence in plasma binding. The results of these studies suggest that plasma protein binding plays a major role in determining the values of CLp of L-692,429 among the species. After an intravenous dose of [3H]L-692,429 to rats, liver, kidney, lung, and heart had the highest levels of radioactivity at the early time points, but the gastrointestinal tract had increasing concentrations at later time points. Most of the radioactivity was cleared from all tissues by 24 hr, indicating that L-692,429 did not accumulate in tissues. After intravenous dosing of [3H]L-692,429 to rats and dogs, recoveries of total radioactivity in urine and feces corresponded to approximately 10% and 90%, respectively. Greater than 70% of radioactivity was recovered in bile of rats within 24 hr after intravenous dosing of [3H]L-692,429, indicating that biliary excretion was the primary route of elimination. Based on the combined recoveries of the radioactive dose in bile and urine after an oral dose of L-692,429, oral absorption in rats was approximately 3%. The poor absorption may be the result of the zwitterionic nature of this compound.
Assuntos
Benzazepinas/farmacocinética , Tetrazóis/farmacocinética , Animais , Benzazepinas/uso terapêutico , Bile/metabolismo , Proteínas Sanguíneas/metabolismo , Cães , Avaliação Pré-Clínica de Medicamentos , Fezes , Hormônio do Crescimento/deficiência , Humanos , Técnicas In Vitro , Injeções Intravenosas , Masculino , Pan troglodytes , Ligação Proteica , Ratos , Ratos Sprague-Dawley , Tetrazóis/uso terapêutico , Distribuição Tecidual , UrinaRESUMO
Recent studies have indicated that the nephrotoxicity of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether ("Compound A"), a breakdown product of the inhaled anesthetic sevoflurane, may be mediated by a reactive intermediate(s) generated via the cysteine conjugate beta-lyase pathway. In order to gain a better understanding of glutathione (GSH)-dependent metabolism of Compound A, the present study was carried out with the primary goal of detecting and characterizing Compound A--GSH conjugates. By means of ionspray LC-MS/MS and NMR spectroscopy, a total of four GSH conjugates ("A1-A4") were identified from the bile of rats dosed intraperitoneally with Compound A. A1 and A2 were identified as two diastereomers of S-[1,1-difluoro-2-(fluoromethoxy)-2-(trifluoromethyl)ethyl]glutath ione, while A3 and A4 were identified as (E)- and (Z)-S-[1-fluoro-2-(fluoromethoxy)-2-(trifluoromethyl)-vinyl]glutat hione, respectively. Quantitative analyses indicated that approximately 29% of the administered dose of Compound A was excreted into the bile in the form of the above GSH conjugates over a period of 6 h. Studies conducted in vitro demonstrated that the reaction of Compound A with GSH was catalyzed by both rat liver cytosolic and microsomal glutathione S-transferases (GST), with the two enzyme systems exhibiting different product selectivities. Formation of these GSH conjugates also occurred nonenzymatically at an appreciable rate. These results indicate that spontaneous and enzyme-mediated conjugation with GSH represents a major pathway of metabolism of Compound A in rats. Conjugation of Compound A with GSH in vivo appeared to be catalyzed preferentially by microsomal rather than cytosolic GST, based on comparison of biliary, microsomal, and cytosolic metabolic profiles. By analogy with other haloalkenes, further metabolism of the corresponding cysteine conjugates of Compound A by renal cysteine conjugate beta-lyase may lead to the formation of reactive acylating agents, which would be expected to bind covalently to cellular macromolecules and cause organ-selective nephrotoxicity.
Assuntos
Bile/química , Éteres/análise , Éteres/metabolismo , Éteres/toxicidade , Glutationa/análise , Glutationa/metabolismo , Hidrocarbonetos Fluorados/análise , Hidrocarbonetos Fluorados/toxicidade , Rim/efeitos dos fármacos , Éteres Metílicos , Animais , Cromatografia Líquida , Hidrocarbonetos Fluorados/metabolismo , Masculino , Espectrometria de Massas , Microssomos Hepáticos/metabolismo , Ligação Proteica , Ratos , Ratos Sprague-Dawley , SevofluranoRESUMO
The relative intrinsic in vitro N-glucuronidation reactivity of three classes of heterocyclic compounds was compared using model compounds incubated with UDP-glucuronic acid-enriched liver microsomes from rats, monkeys, and humans. These compounds, all methylbiphenyl (MB) derivatives, represent three classes of N-containing heterocycles commonly used in the design of new drug entities [i.e MB-tetrazole, MB-triazole, (1,2,3- and 1,2,4-), and MB-imidazole (C2- and C4-substituted)]. The structures of all respective N-glucuronides generated from microsomal incubations were determined by Nuclear Overhauser Effect difference NMR spectroscopy. The chemical and enzymic stabilities of N-glucuronides were also studied. In general, relatively low reactivity was found at nitrogens located next to substituted carbons in heterocycles such as N3 in MB-C4-imidazole, N3 in MB-1,2,3-triazole, N2 (or N4) in MB-1,2,4-triazole, and N1 (or N4) in MB-tetrazole. MB-C2-imidazole, in which both nitrogens are in immediate neighboring positions of the substituted carbon, was unreactive toward N-glucuronidation. When the rate of N-glucuronidation was compared under optimal reaction conditions for each compound, most compounds showed higher reactivity with liver microsomes from monkeys than those from rats, except for N2-glucuronidation of MB-tetrazole and MB-1,2,3-triazole. However, the trend for the relative N-glucuronidation reactivity of these compounds by liver microsomes from humans is quite different from those by monkeys and rats.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Compostos de Bifenilo/metabolismo , Glucuronatos/metabolismo , Imidazóis/metabolismo , Microssomos Hepáticos/metabolismo , Tetrazóis/metabolismo , Triazóis/metabolismo , Animais , Sítios de Ligação , Estabilidade Enzimática , Humanos , Concentração de Íons de Hidrogênio , Macaca mulatta , Espectroscopia de Ressonância Magnética/métodos , Masculino , Nitrogênio/metabolismo , Ratos , Ratos Sprague-Dawley , Especificidade da EspécieRESUMO
The disposition and metabolism of [3H]pioglitazone was determined in male rats after oral administration. The peak plasma concentration of 10 micrograms/ml occurred 1 hr after dosing at 10 mg/kg p.o.; the apparent plasma terminal half-life was 7.5 hr. Most of the radioactivity in plasma up to 8 hr after dosing was due to the parent drug. Pioglitazone was highly protein-bound in plasma; only 1-2% was free at concentrations of 0.1-10 micrograms/ml. Within 3 days after oral administration to bile duct-cannulated rats, 36% and 15% of the oral dose was recovered in the bile and urine, respectively. The pattern of biliary and urinary metabolites was similar. A total of eight metabolites were isolated and identified on the basis of NMR spectroscopy and MS. Metabolites resulting from hydroxylation of either carbon adjacent to the pyridine ring were conjugated with glucuronic acid (M7) or sulfuric acid (M6). The metabolite hydroxylated on the terminal carbon of the ethyl side chain was further oxidized to the carboxylic acid derivative (M3). Oxidative loss of the terminal carbon led to a nicotinic acid derivative (M2) and loss of both carbon atoms to the corresponding 3-hydroxypyridine (M9) derivative that was excreted as the sulfate conjugate (M8). The two carboxylic acid metabolites were also conjugated with taurine (M4 and M5).
Assuntos
Hipoglicemiantes/metabolismo , Hipoglicemiantes/farmacocinética , Tiazóis/metabolismo , Tiazóis/farmacocinética , Tiazolidinedionas , Administração Oral , Animais , Proteínas Sanguíneas/metabolismo , Hipoglicemiantes/sangue , Espectroscopia de Ressonância Magnética , Masculino , Espectrometria de Massas , Pioglitazona , Ligação Proteica , Ratos , Ratos Sprague-Dawley , Tiazóis/sangue , Distribuição Tecidual , TrítioRESUMO
Two series of potential angiotensin II antagonists derived from carboxyl-functionalized "diazole" heterocycles have been prepared and evaluated. Initially, a limited investigation of 4-arylimidazole-5-carboxylates led to 2-n-butyl-4-(2-chlorophenyl)-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-y l] methyl]-1H-imidazole-5-carboxylic acid (12b), which was found to be a highly potent antagonist of the rabbit aorta AT1 receptor (IC50 0.55 nM). In conscious, normotensive rats, 12b at 0.1 mg/kg iv inhibited the pressor response to AII by 88%, with a duration of > 6 h. More extensively studied was an isosteric series of 3-alkyl-4-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-pyrazole -5- carboxylates bearing aryl, alkyl, or aralkyl substituents at N1. These compounds were available in highly regioselective fashion via condensation of a substituted hydrazine hydrochloride with a 2-(methoxyimino)-4-oxoalkanoate intermediate. In vitro, the most potent pyrazolecarboxylic acids had n-butyl at C3 and were substituted at N1 by such groups as 2,6-dichlorophenyl (19h), 2-(trifluoromethyl)phenyl (19k), benzyl (19t), and phenethyl (19u), all with IC50 values of 0.18-0.24 nM. Although less potent in the receptor assay, 3-n-propylpyrazolecarboxylic acids were at least as effective as their butyl counterparts in vivo. Several of the pyrazolecarboxylic acid derivatives demonstrated potent, long-lasting oral activity in rats. At 1 mg/kg po, the 1-benzyl-3-butyl (19t), 1-(2,6-dichlorophenyl)-3-propyl (19v), 3-propyl-1-(2,2,2-trifluoroethyl) (19y), and 1-benzyl-3-propyl (19z) analogues all gave > or = 75% inhibition of the AII pressor response in the rat model, with duration of action > 23 h.
Assuntos
Angiotensina II/antagonistas & inibidores , Ácidos Carboxílicos/síntese química , Imidazóis/síntese química , Pirazóis/síntese química , Angiotensina II/farmacologia , Antagonistas de Receptores de Angiotensina , Animais , Aorta/metabolismo , Pressão Sanguínea/efeitos dos fármacos , Ácidos Carboxílicos/farmacologia , Fenômenos Químicos , Físico-Química , Imidazóis/farmacologia , Masculino , Estrutura Molecular , Pirazóis/farmacologia , Coelhos , Ratos , Ratos Sprague-Dawley , Relação Estrutura-AtividadeRESUMO
The microbiological transformation of L-696,474 [1], a novel cytochalasin that is an inhibitor of HIV-1 protease, was investigated using Actinoplanes sp. ATCC 53771. Six hydroxylated metabolites 2-7 of 1 were isolated and purified using reversed-phase hplc. All six metabolites were found to have undergone hydroxylation at the C-16 methyl group (C-22) of 1. Three of the compounds, 3, 4, and 5, were further hydroxylated at the para (C-29), the meta (C-28), and both the para and the meta, positions of the phenyl ring, respectively. Metabolites 6 and 7 were shown to result from vicinal dihydroxylation on both C-16 and its attached Me (C-22). The metabolite 7 was further hydroxylated on the meta position of the phenyl ring. The structures of the metabolites were established using spectroscopic techniques including ms, 1H nmr, 13C nmr, and various 2D nmr spectroscopy experiments.
Assuntos
Actinomycetales/metabolismo , Citocalasinas/metabolismo , Inibidores da Protease de HIV/metabolismo , Sequência de Aminoácidos , Biotransformação , Hidroxilação , Isoindóis , Dados de Sequência MolecularRESUMO
The in vitro metabolism of DuP 753, a novel nonpeptide angiotensin II receptor antagonist, has been investigated in incubations with liver slice preparations from rats, monkeys and humans. Metabolites were identified by HPLC/MS, FAB/MS, Cl/MS, and/or 1H NMR. In the rat, the primary route of metabolism was oxidative, leading to either monohydroxylated or oxidized (carboxylic acid) metabolites, whereas in monkeys, glucuronidation of the tetrazole moiety predominated. An equal mixture of both oxidized and glucuronic acid-conjugated metabolites was isolated from incubations with human liver slices. All metabolites were tested in an in vitro assay to determine their activity as angiotensin II receptor antagonists. The monohydroxylated products and glucuronic acid conjugates were determined to be much less active than DuP 753. Biotransformation to the carboxylic acid, however, was shown to dramatically increase the activity of this agent. The in vivo duration of action of DuP 753 has been observed to be much longer in the rat than in the monkey. This may be explained, at least in part, by these in vitro metabolism studies. The predominance of glucuronidation observed in incubations with monkey liver slices would yield metabolites with diminished activity and might be expected to shorten the in vivo duration of DuP 753 in that species. The oxidative conversion to the carboxylic acid metabolite, along with the low level of glucuronidation observed in incubations with rat liver slices, may be responsible for the prolonged duration observed in vivo in the rat.